SLAMF7 Polyclonal Antibody, Biotin Conjugated
Product Specifications
Background
SLAMF7 contains one Ig-like C2-type (immunoglobulin-like) domain. Isoform 1 mediates NK cell activation through a SAP-independent extracellular signal-regulated ERK-mediated pathway. It may play a role in lymphocyte adhesion. Isoform 3 does not mediate any activation. SAP can bind the cytoplasmic tail of isoform 1 when phosphorylated in the presence of Fyn (in vitro) . SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Expression was detected in NK cells, activated B-cells, NK-cell line but not in promyelocytic, B-, or T-cell lines. The isoform 3 is expressed at much lower level than isoform 1. There are three named isoforms.
Synonyms
19A; 19A24 protein; CD 319; CD2 like receptor activating cytotoxic cells; CD2 subset 1; CD319; CD319 antigen; CRACC; CS1; Membrane protein FOAP 12; Novel Ly9; Novel LY9 lymphocyte antigen 9 like protein; Protein 19A; SLAM family member 7; SLAMF 7.
Swiss Prot
Q9NQ25
Cellular Locus
Cell membrane
Host
Rabbit
Immunogen
51-160/335
Target
SLAMF7
Clonality
Polyclonal
Isotype
IgG
Conjugation
Biotin
Source
KLH conjugated synthetic peptide derived from human SLAMF7
Applications
WB, ELISA
Purification
Purified by Protein A.
Concentration
1µg/µl
Dilution
WB (1:300-5000), ELISA (1:500-1000)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C for 12 months.
Predicted Cross Reactivity
Human, Mouse, Rat, Cow
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
